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Abstract: Metabolic acidosis and metabolic bone disease are frequent complications in patients on
parenteral nutrition (PN). A common contributor to these complications could be a daily high renal
acid load. This study aims to find a method for predicting the potential total acid load (PTAL) and
the pH of the compounded parenteral nutrition mixtures. The pH and titratable acidity (TA) of fifty
compounded mixtures were measured. The potential metabolic acid load (PMAL) was calculated
by considering the amount of nutrients that are acid producers and consumers. The PTAL of the
TPN mixtures was calculated by adding TA to PMAL. Multiple linear regression analyses were used
to develop a predictive model for the TA and pH of the compounded mixtures. The predicted TA
and pH values of the analyzed mixtures agreed with those measured (Passing-Bablok analysis).
The PTAL was >50 mmol/day for 82% of the mixtures, >75 mmol/day for 40% of the mixtures, and
>100 mmol/day for 22% of the mixtures. The prediction of the renal acid load in patients on long-term
PN could allow more appropriate acid-base balancing. Moreover, predicting the pH of such mixtures
could be useful to pharmacists to assess the stability and compatibility of the components in the
compounded mixtures.
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1. Introduction
Parenteral nutrition (PN) may be associated with several metabolic complications including
metabolic acidosis (MA) and metabolic bone disease (MBD). MA during PN may be caused by the
excessive exogenous administration and/or endogenous production of non-volatile acids or by a
reduction in the renal excretion of fixed acid or massive loss of bicarbonate through the gastrointestinal
tract. In PN patients, MA is an under-reported metabolic complication [1] and data on the prevalence
of metabolic disturbances in PN patients are not still comprehensively reported and, depending on the
type of study, ranged from 5% to 25% [1,2]. MBD has a greater prevalence in patients on long-term
artificial nutrition than in the general population with a particularly high prevalence (67–84%) in
patients on long-term PN [3,4]. However, the etiology of MBD in patients on long-term PN is not
well-known [5,6]. Studies indicate that one of the possible causes of this complication could depend
on a chronic, not excessive, renal acid load following daily administration of PN mixtures [7,8].
The intravenous infusion of these mixtures is associated both with already formed non-volatile acids
(titratable acidity, TA) [2,9] and non-volatile acids resulting from the catabolism of some nutrients
(potential metabolic acid load, PMAL). As a consequence, a persistent and imbalanced daily renal acid
load would, therefore, represent a common factor among PN patients with overt MBD. Although it is
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still being debated, one hypothesis [10] that is sometimes confirmed or contradicted [11] describes that
a constant renal acid load triggers the release of alkaline substances from the bone, which are mainly
calcium and carbonates. This is a physiological process that may help the body maintain the pH of the
blood at acceptable biological levels. On the other hand, this would weaken the bone mineral matrix
by causing osteopenia and then osteoporosis over time. In patients exclusively receiving PN, the
renal acid load depends entirely on the qualitative and quantitative composition of the compounded
mixture used for parenteral nutrition. The prediction of the potential total acid load (PTAL) of the
mixture could allow the nutrition specialist to balance the components of the mixture to obtain a very
low or nil PTAL. The primary purpose of this study was to develop a predictive equation for the PTAL
based on the content of all components in a compounded PN mixture. The secondary aim of the study
was to then develop an equation for predicting the pH. The pH of the compounded mixtures for PN
does not play a role in the evaluation of the PTAL because the free acidity (pH) is already included in
the TA and a compounded mixture may have a relatively low pH but a very low, none, or negative
PTAL. However, having the knowledge of the compounded mixture’s pH in advance is important
because pH is the leading factor used for predicting the stability and compatibility of the components
of such mixtures.
2. Materials and Methods
Fifty patients receiving individualized compounded mixtures of PN were evaluated by the
Clinical Nutrition Unit of Federico II University Medical School. The compounding of PN mixtures
was carried out using an automatic filler (SIFRAMIX filling system, Fresenius Kabi Italia, Isola della
Scala, Italy) in which the nutrients in the bag were added in the following order of processing: water,
glucose, and amino acids simultaneously. The order of addition of electrolytes was first sodium and
then potassium, magnesium, calcium, and 1,6-diphosphate. Lipid was added at the same time of the
other macronutrients but in a separate compartment of the bag. The nutrients used to compound
the mixtures were as follows: 10% Sintamin (5000 mL bag, Fresenius Kabi Italia, Isola della Scala,
Italy), 50% glucose (5000 mL bag, GalenicaSenese, Monteroni d’Arbia, Italy), 20% Smoflipid (500 mL
bottle, Fresenius Kabi Italia, Isola della Scala, Italy), 6% gluconate calcium (250 mL bottle, Bioindustria,
Novi Ligure, Italy), 0.5 mmol/mL magnesium sulfate (250 mL bottle, Bioindustria, Novi Ligure, Italy),
10 g/100 mL D-fructose 1,6-diphosphate disodium salt hydrate (100 mL bottle, Biomedica Foscama
Group Spa, Ferentino, Italy), 3 mmol/mL sodium chloride (250 mL bottle, Bioindustria, Novi Ligure,
Italy), 3 mmol/mL potassium chloride (250 mL bottle, Fresenius Kabi Italia, Isola della Scala, Italy), and
water for injections (5000 mL bag, GalenicaSenese, Monteroni d’Arbia, Italy). We recommend adding
vitamins (Soluvit and Vitalipid) and trace elements (Addamel N) to the PN mixtures immediately
before the infusion. The pH of the mixtures was measured by using a Beckman Φ40 pHmeter, which
was calibrated with three standards at pH values of 4, 7, and 10. TA was measured in millimoles by
adding 0.1 M NaOH until pH equaled 7.4. The pH and TA measurements of the tested PN mixtures
were made in duplicate at room temperature immediately after compounding and after subsequent
storage for one day at room temperature. This is roughly the time needed for infusion. According to
the standard method, a precision of ±0.02 pH unit and an accuracy of ±0.05 pH unit was accepted.
The pH values are reported to the nearest 0.01 pH units. The TA values are reported to the nearest
0.1 mmol units. PMAL was calculated by summing the millimoles of non-volatile acid producers
(cysteine, methionine, lysine, histidine, arginine, and phospholipids) and by subtracting the millimoles
of fixed acid consumers (acetate and gluconate) included in the analyzed mixtures. The PMAL of
compounded mixtures prescribed for PN patients was calculated using the formula below.
PMAL (mmol) = [(2 × cysteine) + (2 × methionine) + lysine + histidine + arginine +
(phospholipids/5) − acetate − gluconate] × (volume/1000).
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Cysteine, methionine, lysine, histidine, arginine, phospholipids, acetate, and gluconate are
expressed in mM and volume is expressed in ml. The anionic amino acids (aspartate and glutamate)
were not considered in the calculation because they were not present in the amino acid solution (10%
Sintamin) used for the compounding of patient-specific mixtures. The anionic acetate was present in
the amino acid solution as stabilizing (85 mmol/L) and the anionic gluconate derived from the calcium
gluconate. The phospholipids were from the lipid emulsion, 15 mmol/L (20% Smoflipid). The PTAL
of the PN mixtures was calculated as the algebraic sum of the TA and the PMAL.
3. Statistics
Multiple linear regression analyses (based on the quantitative and qualitative composition of
the analyzed mixtures and on pH and TA measurements) were used to develop a predictive model
for pH and TA. pH and TA measurements of the PN mixtures were carried out after mixing for
each preparation. This included the prescribed doses of all components. The agreement between the
experimental results and those provided by the multilinear model was evaluated by the Passing-Bablok
non-parametric regression analysis and by the Bland-Altman plot. Two-sided p values less than 0.05
were considered statistically significant.
4. Results
Table 1 shows the mean, the standard deviation, and the minimum-maximum concentrations of
the components utilized in the compounding of the evaluated parenteral nutrition mixtures.
Table 1. Mean ± SD and minimum-maximum (min–max) values of the volume, osmolarity, and
concentration of components in the compounded parenteral mixtures evaluated in thestudy (n = 50).
Mean± SD Min–Max
Volume (mL) 1979 ± 574 630–3000
Osmolarity (mOsm/L) 1013 ± 236 419–1515
Glucose (g/100 mL) 9.1 ± 3.1 3.0–21.1
Lipid (g/100 mL) 2.2 ± 0.7 0–3.6
Amino Acid (g/100 mL)) 3.3 ± 1.2 1.1–6.1
Calcium (mmol/L) 3.0 ± 2.2 0–14.3
Phosphorous (mmol/L) 6.1 ± 4.4 0–18.6
Sodium (mmol/L) 51.1 ± 18.0 15.0–90.0
Potassium (mmol/L) 25.2 ± 13.4 0–73.4
Magnesium (mmol/L) 4.6 ± 2.7 1.2–13.2
Acetate (mmol/L) 29.1 ± 10.5 9.6–53.7
Gluconate (mmol/mL) 5.8 ± 4.1 0–27.1
Chloride (mmol/mL) 76.3 ± 25.6 31.4–140.0
4.1. Predictive Equations for the Titratable Acidity and the pH of TPN Mixtures
The amount of the nutrients added to each mixture was used for creating predictive equations
for TA and pH. Multiple regression analyses (method enter: dependent variable = measured TA,
independent variables = concentration of all constituents of the mixture; r = 0.998, p < 0.0001) generated
the equation below.
TApredicted (mmol) = [0.769 + (−0.029 × glucose) + (0.619 × lipid) + (1.001 × amino acid) +
(0.078 × calcium) + (0.487 × phosphorous) + (−0.004 × sodium) + (0.002 × potassium) +
(−0.070 × magnesium)] × (volume/1000).
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When using the measured pH (r = 0.959, p < 0.0001) as the dependent variable, the equationbelow
was obtained.
pHpredicted = 5.894 + (−0.007 × glucose) + (0.026 × lipid) + (0.050 × amino acid) +
(0.009 × calcium) + (−0.036 × phosphorous) + (−0.001 × sodium) +
(0.0003 × potassium) + (−0.003 × magnesium).
These two predictive equations led to the prediction of the total titratable acidity (TApredicted) and
the pH (pHpredicted) of the compounded mixtures, according to the content of their constituents.
Glucose, lipids, and amino acids are expressed in g/100 mL. Calcium (as calcium gluconate),
phosphorus (as D-fructose 1,6-diphosphate disodium salt hydrate), sodium (as sodium chloride),
potassium (as potassium chloride), and magnesium (as magnesium sulfate) are expressed in mM.
4.2. Comparison of Measured and Predicted Titratable Acidity and pH
Measured and predicted TA and pH values of the evaluated mixtures were normally distributed
(Kolmogorov-Smirnorv test, p = 0.20). The mean, 95% confidence interval, and minimum and
maximum of the measured and predicted TA and pH are shown in Table 2. Figure 1A,B depict
the scatter-plot with the trend and the identity lines between the measured and predicted values of TA
and pH, respectively. The cusum test for the linear model of the measured and predicted values did not
show significant deviations from linearity for TA (p = 0.44) or pH (p = 0.26) and allowed the application
of the Passing-Bablok regression. The Passing-Bablok regression equation for measured and predicted
TA was as follows: Y = 1.001X − 0.040. The 95% confidence intervals (95% CIs) for the slope and the
intercept were 0.987 to 1.024 and −0.281 to 0.201, respectively. The Passing-Bablok regression equation
for the measured and predicted pH was as follows: Y = 0.939X + 0.360; 95% CI = 0.842 to 1.035 for the
slope and 95% CI= −0.181 to 0.923 for the intercept. For both equations, the 95% CI for the trend line
coefficients contained 0 for the intercept and 1 for the slope, which validated the congruity between
the measured and predicted values for both TA and pH. Figure 2A,B show the Bland-Altman plots for
the measured and predicted values of TA and pH, respectively. In both graphs, the points are scattered
within the two 95% CIs for the means of the differences, which shows that the predicted results were
in agreement with the measured ones. Vitamins and trace elements didn’t significantly alter the pH
or TA of the PN mixture. Typically, the pH and TA values of a mixture before and after addition of
vitamins and trace elements were at a pH 5.98–6.01 and a TA 18.33–18.37 mmol of NaOH, respectively.
Figure 1. Scatter-plot with the regression line (calculated according to the Passing-Bablok method) and
the identity line for the measured and predicted values of titratable acidity (TA), (A) and pH (B). TA is
expressed in millimoles of NaOH added until pH = 7.4.
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Table 2. Mean, 95% confidence interval (95% CI), and minimum-maximum (min–max) values of the
measured and predicted titratable acidity (TA) and pH of compounded parenteral mixtures evaluated
in this study (n = 50).
Mean (95% CI) Min–Max
Measured TA (mmol) 15.2 (13.6–16.8) 3.7–25.3
Predicted TA (mmol) 15.2 (13.6–16.8) 3.8–25.0
Measured pH 5.73 (5.68–5.78) 5.31–6.03
Predicted pH 5.74 (5.69–5.79) 5.28–6.04
Figure 2. Bland-Altman plots for the measured and predicted values of titratable acidity (TA), (A) and
pH (B).
4.3. Calculation of the Potential Metabolic Acid Load
Table 3 shows the mean, the standard deviation, and the minimum–maximum concentration of
producers and consumers of non-volatile acids after their metabolization.
Table 3. Mean ± SD and minimum-maximum (min–max) values of the concentration of substances in
the compounded parenteral mixtures evaluated in this study (n = 50) that affect the renal acid load
after their metabolism.
Mean± SD Min–Max
Cysteine (mmol/L) 0.4 ± 01 0.1–0.7
Methionine (mmol/L) 12.0 ± 4.3 4.0–22.2
Lysine (mmol/L) 17.0 ± 6.1 5.6–31.4
Arginine (mmol/L) 18.5 ± 6.7 6.1–34.2
Histhidine (mmol/L) 7.2 ± 2.6 2.4–13.4
Phospholipid (mmol/L) 1.5 ± 0.5 0–2.6
Acetate (mmol/L) 29.1 ± 10.5 9.6–53.7
Gluconate (mmol/L) 5.8 ± 4.1 0–27.1
4.4. Calculation of the Potential Total Acid Load
The PTAL of the TPN mixtures was calculated using the following equation: PTAL = TA + PMAL.
Table 4 shows the mean, the standard deviation, and the minimum and maximum of TA, PMAL, and
PTAL. The data showed that, on average, approximately 80% of the PTAL depended on the PMAL
and the remaining percentage was from the preformed non-volatile acids. The PTAL values of the fifty
considered mixtures were between approximately 5 and 152 mmol/day. Regarding the distribution of
these values, the PTAL was >50 mmol/day in the 82% of the mixtures (41/50), >75 mmol/day in 40%
(20/50), and >100 mmol/day in 22% of the mixtures (11/50).
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Table 4. Mean ± SD and minimum-maximum (min–max) values of the measured titratable acidity
(TA), the calculated potential metabolic acid load (PMAL), and the potential total acid load (PTAL) in
the compounded parenteral mixtures evaluated in this study (n = 50).
Mean± SD Min–Max
TA (mmol) 15.2 ± 5.7 3.7–25.3
PMAL (mmol) 65.1 ± 28.5 −0.6–131.9
PTAL (mmol) 80.3 ± 32.6 5.3–151.8
5. Discussion
A risk of metabolic acidosis associated with PN in patients without renal dysfunction or
bicarbonate loss is clearly correlated with an excessive and acute renal acid load that could be due to
the content of both preformed non-volatile acids and non-volatile acids that result from the catabolism
of nutrients present in the administered mixture [12]. The preformed non-volatile acids originate
from the chlorine, phosphate, or sulfate anions of PN mixture components or from the inorganic
acids added to the single solutions of macronutrients (lipid emulsion, amino acid mixture, and
glucose) and electrolytes to maintain their stability over time or to reach an advantageous pH for the
physical-chemical stability of the compounded mixture after their mixing. The fixed acidity produced
by the catabolism of nutrients when compared to energy is called “potential” because it depends on
the amino acids’ metabolic fate. In patients with a nil nitrogen balance where the body protein content
remains constant, the amount of amino acids administered equals that of protein turnover. Since the
amino acids from protein turnover are all sent to the oxidative degradation pathway, the production of
non-volatile acids is equal to the amount of amino acids acid producers provided with the mixtures. In
patients with a positive or negative nitrogen balance, the metabolic production of non-volatile acids
could be reduced or increased compared to the amino acid content administered in the parenteral
nutrition mixtures. Our results show that the non-volatile acid producers compared to the preformed
non-volatile acids considerably affect (80% on average) the PTAL of the compounded PN mixtures.
Studies report that the MA is mainly caused by the addition of preformed inorganic acids to adjust
the pH in a favorable range and improve the stability of the compounded PN mixture [2–9] rather
than the acidity of metabolic origin. In any case, it is reasonable to assume that, when the daily PTAL
significantly exceeds the capacity of body buffer systems in the event of impaired renal function or
when an excessive loss of bicarbonate occurs, it is highly probable that acute MA may occur if the
infusion of a mixture with an elevated PTAL is performed at high speed. This is a relevant clinical
event with the pathological reduction of pH, bicarbonates, and the partial pressure of carbon dioxide
in the arterial blood, which generally requires a timely medical intervention. On the other hand,
chronic MA with secondary osteopenia or osteoporosis shows a slight reduction in the arterial blood
pH, which could still be within the values considered normal [13]. MBD associated with long-term
PN has an etiology not still fully explained and is likely related to several persistent factors such as
chronic malnutrition, multiple vitamin and mineral deficiencies, drug use such as corticosteroids,
contaminants present in the solutions used for the compounding of PN mixtures (e.g., aluminum),
and underlying pathologies [5,6]. What is certain is that MBD is common in long-term PN patients
and is characterized by initially asymptomatic osteopenia/osteoporosis that becomes evident over
time and includes bone pain and increased risk of fractures. It has been suggested that MBD may
be due to a silent chronic acidemia [13,14] that would activate a slow but constant release of alkaline
substances from the bone to balance the daily acid load. By this mechanism, the HCO3¯ and pH values
in the blood would still fall within the limits considered “normal” but would be slightly below the
ideal value. This would help maintain the activity of the stimuli (as an increase in renal excretion of
NH4+, H+, and H2PO4− ions or renal generation/recovery of bicarbonate ions) for the homeostatic
adaptations necessary to achieve the appropriate acid-base balance. When the renal mechanisms
involved in acid-base balance are insufficient to counterbalance a high and persistent PTAL, a release
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of alkaline substances from the bone occurs, which helps to maintain the blood pH at acceptable levels
for the body but at the cost of bone mineral depletion over time.
The results of the present study show that a significant percentage of patients on PN are exposed
daily to a potential renal acid load greater than 50 mmol. In several cases, the potential renal acid
load exceeds 100 mmol/day, which predisposes patients to MA or possible metabolic complications
of the bone. As a consequence, it is evident that the prediction of the daily PTAL in long-term PN
patients becomes essential for the prevention of these complications. The use of a simple equation for
predicting the acid load related to the quality and quantity of constituents coupled with the simple
calculation of the PMAL resulting from the nutrients’ metabolism used for PN could be a useful
tool available to the nutrition specialist to balance the PTAL of the mixtures for infusion. If feasible,
the PTAL of the mixture could be corrected by adding the right dose of organic acids or salts of organic
acids such as acetate, gluconate, aspartate, or citrate without interfering significantly on the final pH of
the compounded mixture. Otherwise, the nutrition specialist could provide an additional parenteral
administration separately from the PN mixture of alkalinizing solutions (e.g., potassium lactate or
sodium bicarbonate) to balance the daily acid load following the administration of the PN mixture.
This would be of particular utility in long-term PN patients. Therefore, it could be recommended
to pharmacists to report the daily PTAL on the label of the compounded mixture together with
the information on the added nutrients. The authors can provide only general hints about how to
balance the acid load due to the mixture infusion. The choice to change the type of nutrient used, e.g.,
potassium aspartate or acetate instead of potassium chloride, must be agreed between pharmacist and
nutrition specialist since the anions of organic acids may not be tolerated by the patient or could affect
the stability of the mixture. Therefore, it will be based on the pharmacist’s experience (to evaluate the
possibility of a direct acid-base balance of the mixtures) and the clinical evaluation of the patient by
the nutrition specialist that will be taken into consideration on a case-by-case basis.
Furthermore, predicting the pH of the mixture for PN based on the quantity and quality of its
components could be very useful to the pharmacist for checking the stability and compatibility of
the mixture constituents. A pH between 5.0 and 5.5 generally ensures an unsuitable environment
for the precipitation of calcium phosphates [15], prevents the formation of toxic chemical species
from the reaction between glucose and amino acids (Maillard reaction) [16,17], and discourages the
aggregation and coalescence of the micelles present in the lipid emulsion when they enter into contact
with the other components of the mixture [18]. Obviously, the predictive equations for the PTAL and
pH of the compounded mixtures depend not only on the amount but also on the type of nutrients
and electrolytes present in the utilized solutions. A wide range of electrolytes and macronutrients are
commercially available and various pharmaceutical companies use different acidification methods
to stabilize such solutions. Consequently, for each set of new products, it is necessary to perform
a number of acid-base titrations on the compounded mixtures to establish, with a good margin of
accuracy, the predictive equations for both PTAL and pH.
6. Conclusions
This study suggests a method for predicting the pH and the potential renal acid load of
compounded parenteral nutrition mixtures to which adult long-term PN patients are exposed to daily.
The prediction of the renal acid load may be of great utility to nutrition specialists since the knowledge
of this value would allow a most appropriate acid-base balancing that would avoid or reduce some
metabolic complications associated with long-term PN. Regarding PN patients who are in mixed
nutrition such as parenteral and enteral nutrition or diet or oral nutritional supplements, the nutrition
specialist will evaluate the additional acid load from sources other than the PN. Furthermore, although
the pH of such mixtures does not affect the renal acid load, it could be useful to pharmacists in
predicting the stability and compatibility of the many components added in the compounded mixtures.
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References
1. Jones, B.J.; Chopra, P.; Groning, J.; Deel-Smith, P. Acid-base disturbance during home parenteral
nutrition—An observational cohort study. e-SPEN Eur. e-J. Clin. Nutr. Metab. 2011, 6, e31–e35. [CrossRef]
2. Kato, K.; Sugiura, S.; Yano, K.; Fukuoka, T.; Itoh, A.; Nagino, M.; Nabeshima, T.; Yamada, K. The Latent Risk
of Acidosis in Commercially Available Total Parenteral Nutrition (TPN) Products: A Randomized Clinical
Trial in Postoperative Patients. J. Clin. Biochem. Nutr. 2009, 45, 68–73. [CrossRef] [PubMed]
3. Cohen-Solal, M.; Baudoin, C.; Joly, F.; Vahedi, K.; D’Aoust, L.; De Vernejoul, M.C.; Messing, B. Osteoporosis
in patients on long-term home parenteral nutrition: A longitudinal study. J. Bone Miner. Res. 2003, 18,
1989–1994. [CrossRef] [PubMed]
4. Pironi, L.; Labate, A.M.; Pertkiewicz, M.; Przedlacki, J.; Tjellesen, L.; Staun, M.; De Francesco, A.; Gallenca, P.;
Guglielmi, F.W.; Van Gossum, A.; et al. Prevalence of bone disease in patients on home parenteral nutrition.
Clin. Nutr. 2002, 21, 289–295. [CrossRef] [PubMed]
5. Buchman, A.L.; Moukarzel, A. Metabolic bone disease associated with total parenteral nutrition. Clin. Nutr.
2000, 19, 217–231. [CrossRef] [PubMed]
6. Hamilton, C.; Seidner, D.L. Metabolic bone disease and parenteral nutrition. Curr. Gastroenterol. Rep. 2004, 6,
335–341. [CrossRef] [PubMed]
7. Berkelhammer, C.H.; Wood, R.J.; Sitrin, M.D. Acetate and hypercalciuria during total parenteral nutrition.
Am. J. Clin. Nutr. 1988, 48, 1482–1489. [CrossRef] [PubMed]
8. Bengoa, J.M.; Sitrin, M.D.; Wood, R.J.; Rosenberg, I.H. Amino acid-induced hypercalciuria in patients on
total parenteral nutrition. Am. J. Clin. Nutr. 1983, 38, 264–269. [CrossRef] [PubMed]
9. Sugiura, S.; Inagaki, K.; Noda, Y.; Nagai, T.; Nabeshima, T. Acid load during total parenteral nutrition:
Comparison of hydrochloric acid and acetic acid on plasma acid-base balance. Nutrition 2000, 16, 260–263.
[CrossRef]
10. Green, J.; Kleeman, C.R. Role of bone in regulation of systemic acid-base balance. Kidney Int. 1991, 39, 9–26.
[CrossRef] [PubMed]
11. Bonjour, J.P. Nutritional disturbance in acid-base balance and osteoporosis: A hypothesis that disregards the
essential homeostatic role of the kidney. Br. J. Nutr. 2013, 110, 1168–1177. [CrossRef] [PubMed]
12. Dounousi, E.; Zikou, X.; Koulouras, V.; Katopodis, K. Metabolic acidosis during parenteral nutrition:
Pathophysiological mechanisms. Indian J. Crit. Care Med. 2015, 19, 270–274. [CrossRef] [PubMed]
13. Alpern, R.J.; Sakhaee, K. The clinical spectrum of chronic metabolic acidosis: Homeostatic mechanisms
produce significant morbidity. Am. J. Kidney Dis. 1997, 29, 291–302. [CrossRef]
14. Vormann, J.; Goedecke, T. Acid-Base Homeostasis: Latent Acidosis as a Cause of Chronic Diseases.
Schweiz. Z. Ganzheitsmed. 2006, 18, 255–266. [CrossRef]
Pharmaceutics 2018, 10, 43 9 of 9
15. Allwood, M.C.; Kearney, M.C. Compatibility and stability of additives in parenteral nutrition admixtures.
Nutrition 1998, 14, 697–706. [CrossRef]
16. Fry, L.K.; Stegink, L.D. Formation of Maillard reaction products in parenteral alimentation solutions. J. Nutr.
1982, 2, 1631–1637. [CrossRef] [PubMed]
17. Martins, S.; Jongen, W.; van Boekel, M. A review of Maillard reaction in food and implications to kinetic
modelling. Trends Food Sci. Technol. 2001, 11, 364–373. [CrossRef]
18. Washington, C. Stability of lipid emulsions for drug delivery. Adv. Drug Deliv. Rev. 1996, 20, 131–145.
[CrossRef]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
